|
[1]亚太区肝病研究协会丙型肝炎协助组.亚太区肝病年会丙型肝炎诊治专家共识[J].中华实验和临床感染病杂志, 2007, 1 (1) :88-94.
|
|
[2]Gordon SC.Treatment of viral hepatitis-2001[J].Ann Med, 2001, 33 (6) :385-390.
|
|
[3]Fried MW, Shiffman ML, Reddy KR, et al.Peginterferon al-pha-2a plus ribavirin for chronic hepatitis C virus infection[J].N Engl J Med, 2002, 347 (13) :975-982.
|
|
[4]Hadziyannis SJ, Sette HJ, Morgan TR, et al.Peginterferon alpha-2a and ribavirin combination therapy in chronic hepati-tis C:a randomized study of treatment duration and ribavirin dose[J].Ann Intern Med, 2004, 140 (5) :346-355.
|
|
[5]Zeuzem S, Pawlotsky JM, Lukasiewicz E, et al.Internation-al, multicenter, randomized, controlled study comparing dy-namically individualized versus standard treatment in patients with chronic hepatitis C[J].J Hepatol, 2005, 43 (2) :250-257.
|
|
[6]Ghany MG, Strader DB, Thomas DL, et al.Diagnosis, manage-ment, and treatment of hepatitis C:an update[J].Hepatology, 2009, 49 (4) :1335-1374.
|
|
[7]Pawlotsky JM.Treating hepatitis C in“difficult-to-treat”patients[J].N Engl J Med, 2004, 351:422-423.
|
|
[8]Fried MW, Jensen DM, Rodriguez-Torres M, et al.Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics:randomized study of higher doses of pegjnter-feron alpha-2a and ribavirin[J].Hepatology, 2008, 48 (4) :1033-1043.
|
|
[9]Alberti A.What are the comorbidities influencing the man-agement of patients and the response to therapy in chronic hepatitis C?[J].Liver Int, 2009, 29 (Suppl1) :15-18.
|
|
[10]庄辉, Tracy L, 崔怡辉, 等.我国部分地区丙型肝炎病毒基因分型研究[J].中华流行病学杂志, 2001, 22 (2) :99-101.
|
|
[11]Shifman ML, Suter F, Bacon BR, et al.Peginterferon alfa-2a and fibavirin for16or24weeks in HCV genotype2or3[J].N Engl J Med, 2007, 357 (2) :124-134.
|
|
[12]Yu JW, Wang GQ, Sun LJ, et al.Predictive value of rapid virological response and early virological response on sus-tained virological response in HCV patients treated with pegy-lated interferon alpha-2a and ribavirin[J].J Gastroenterol Hepatol, 2007, 22 (6) :832-836.
|
|
[13]Dalgard O, Mangia A.Short-term therapy for patients with hepatitis C virus genotype2or3infection[J].Drugs, 2006, 66 (14) :1807-1815.
|
|
[14]Jensen DM, Morgan TR, Marcellin P, et al.Early identifica-tion of HCV genotype l patients responding to24weeks peginterferon alpha-2a (40kd) /ribavirin therapy[J].Hepa-tology, 2006, 43 (5) :954-960.
|
|
[15]Marcellin P, Heathcote EJ, Craxi A.Which patients with geno-type l chronic hepatitis C can benefit from prolonged treatment with the‘accordion’regimen?[J].J Hepatol, 2007, 47 (4) :580-587.
|
|
[16]Orito E, Mizokami M, Suzuki K, et al.Loss of serum HCV RNA at week4of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C[J].J Med Virol, 1995, 46 (2) :109-115.
|
|
[17]Bressler BL, Guindi M, Tomlinson G, et al.High body massindex is an independent risk factor for nonresponse to antivi-ral treatment in chronic hepatitis C[J].Hepatology, 2003, 38 (3) :639-644.
|
|
[18]Jacobson IM, Brown RS Jr, McCone J, et al.Impact of weight-based ribavirin with peginteferon alfa-2b in African Americans with hepatitis C virus genotype1[J].Hepatolo-gy, 2007, 46 (4) :982-990.
|
|
[19]Castera L.Steatosis, insulin resistance and fibrosis progres-sion in chronic hepatitis C[J].Minerva Gastroenterol Dietol, 2006, 52 (2) :125-134.
|
|
[20]Soresi M, Tripi S, Franco V, et al.Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis[J].Liver Int, 2006, 26 (9) :1119-1125.
|
|
[21]Cortez-Pinto H.Concluding remarks:metabolic syndrome, liver and HCV[J].Aliment Pharmacol Ther, 2005, 22 (Suppl 2) :83-85.
|
|
[22]Westin J, Lagging M, Dhillon AP, et al.Impact of hepatic steatosis on viral kinetics and treatment outcome during anti-viral treatment of chronic HCV infection[J].J Viral Hepat, 2007, 14 (1) :29-35.
|
|
[23]D’Souza R, Sabin CA, Foster GR.Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy[J].Am J Gastronenterol, 2005, 100 (7) :1509-1515.
|
|
[24]Conjeevaram HS, Kleiner DE, Everhart JE, et al.Race, in-sulin resistance and hepatic steatosis in chronic hepatitis C[J].Hepatology, 2007, 45 (1) :80-87.
|
|
[25]Romero-Gomez M, Del Mar Viioria M, Andrade RJ, et al.Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients[J].Gastroenterology, 2005, 128 (3) :636-641.
|
|
[26]Bueverov AO, Griazin AE, IvashkinVT, et al.Apoptosis of peripheral blood mononuclears and evaluation of the effec-tiveness of antiviral therapy of chronic C hepatitis[J].Klin Med (Mosk) , 2006, 84 (9) :39-44.
|
|
[27]Katayama K, Kasahara A, Sasaki Y, et al.Immunological re-sponse to interferon-gamma priming prior to interferon-al-pha treatment in refractory chronic hepatitis C in relation to viral clearance[J].J Viral Hepat, 2001, 8 (3) :180-185.
|
|
[28]Ishii K, Takamura N, Shinohara E, et al.Intracellular cytokineanalysis of CD4-positive T cells predictive of sustained re-sponse to interferon therapy for patients with chronic hepati-tis C[J].Dig Dis Sci, 2002, 47 (4) :778-783.
|
|
[29]Mihm U, Herrmann E, Sarrazin U, et al.Association of ser-um interleukin-8with virologic response to antiviral therapy in patients with chronic hepatitis C[J].J Hepatol, 2004, 40 (5) :845-852.
|
|
[30]何智敏, 赵艳, 张永宏, 等, 丙型肝炎患者基线T细胞分化状态与快速病毒学应答的相关性分析[J].首都医科大学学报, 2009, 30 (6) :775-779.
|
|
[31]Ge D, Fellay J, Thompson AJ, et al.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance[J].Na-ture, 2009, 461 (7262) :399-401.
|
|
[32]Thomas DL, Thio CL, Martin MP, et al.Genetic variation in lL28B and spontaneous clearance of hepatitis C virus[J].Nature, 2009, 461 (7265) :798-801.
|
|
[33]Suppiah V, Moldovan M, Ahlenstiel G, et al.IL28B is asso-ciated with response to chronic hepatitis C interferon—alpha and ribavirin therapy[J].Nat Genet, 2009, 41:1100-1104.
|
|
[34]McHutchison JG, Lawitz EJ, Shiffman ML, et al.Peginter-feron alfa-2b or alfa-2a with ribavirin for treatment of hepa-titis C infection[J].N Engl J Med, 2009, 361 (10) :580-593.
|
|
[35]Liu CH, Liu CJ, Lin CL, et al.Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hep-atitis C virus genotype1infection:a multicenter, randomized controlled trial[J].Clin Infect Dis, 2008, 47 (10) :1260-1269.
|
|
[36]Rauch A, Kutalik Z, Descombes P, et al.Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure a genome-wide association study[J].Gastroenter-ology, 2010, 138 (4) :1338-1345.
|
|
[37]Tanaka Y, Nishida N, Sugiyama M, et al.Genome-wide association of IL-28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C[J].Nat Genet, 2009, 41 (10) :1105F-1109F.
|
DownLoad: